SCHEMBL758139

SCHEMBL758139

C[C@H](O)C(c1ccco1)N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.43
POLB P06746 1/20 0.43
ADORA2A P29274 2/20 0.42
ADORA1 P30542 1/20 0.42
HTT P42858 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPT P10636 2/20 0.42
NPC1 O15118 1/20 0.42
MAPK1 P28482 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TSHR P16473 1/20 0.42
ABCB1 P08183 2/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
USP2 O75604 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ATM Q13315 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CHRM2 P08172 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6127193 0.77 ALDH1A1 (0.55) GPR119ADORA2AHTTALDH1A1MAPT
SCHEMBL29313174 0.75 NPC1 (0.46) ALDH1A1MAPTNPC1RAB9AL3MBTL1
SCHEMBL9048604 0.74 KMT2A (0.63) POLBHTTALDH1A1MAPK1TSHR
SCHEMBL27365987 0.72 USP2 (0.50) POLBHTTALDH1A1MAPTNPC1
SCHEMBL5599546 0.72 USP2 (0.53) GPR119POLBHTTALDH1A1MAPT
SCHEMBL13556486 0.72 KMT2A (0.47) GPR119POLBADORA2AADORA1HTT
SCHEMBL3805489 0.71 CYP2D6 (0.57) GPR119HTTALDH1A1MAPTNPC1
SCHEMBL8115616 0.71 CYP2D6 (0.57) GPR119HTTALDH1A1MAPTNPC1
SCHEMBL9048938 0.71 MEN1 (0.57) POLBHTTALDH1A1MAPTMAPK1
SCHEMBL8510395 0.71 USP2 (0.51) GPR119POLBHTTALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1954678-B1 NOVEL NK1 AND NK2 ANTAGONISTS ABBOTT PRODUCTS GMBH (DE) 2012-03-21 EP disclosed
US-7592344-B2 NK1 and NK2-antagonists and compositions and methods of using the same SOLVAY PHARMACEUTICALS GMBH (DE) 2009-09-22 US disclosed
EP-1954678-A1 NOVEL NK1 AND NK2 ANTAGONISTS Solvay Pharmaceuticals GmbH (DE) 2008-08-13 EP disclosed
US-20070149537-A1 NK1 and NK2-antagonists and compositions and methods of using the same SOLVAY PHARMACEUTICALS GMBH (DE) 2007-06-28 US disclosed
WO-2007063086-A1 NOVEL NK1 AND NK2 ANTAGONISTS SOLVAY PHARMACEUTICALS GMBH (DE) 2007-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149537-A1 NK1 and NK2-antagonists and compositions and methods of using the same HRH2, PROKR2, BDKRB2 GPR119 437/4885POLB 3628/4885ADORA2A 434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.